All News

ACRmtg.jpg (keep)

Industry Press Releases - BMS, Abbvie, UCB, Janssen

Jack Cush, MD

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to review and look for in the meeting.

Read Article
exhibitor.floor.ACR

Industry Abstract Previews #ACR21 - Horizon, Aurinia, AstraZeneca

Jack Cush, MD

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to review and look for in the meeting.

Read Article
URI.infection.COrona.jpg

Infection Rates in Psoriatic Arthritis Patients on Biologics Have Decreased

ACR

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.

Read Article
guidelines.recommendations.jpg

Management of Immune-Related Adverse Events - ASCO Guideline

Jack Cush, MD

The American Society of Clinical Oncology, Inc (ASCO) has updated its guidelines and recommendations for the management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. Below are select statements from this guideline.

Read Article
PSO.Palmoplantar.jpg

Biologic Use and the Risk of Serious Infection in Psoriasis Patients

Jack Cush, MD

National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or apremila

Read Article
#ACR21 #ACRBest @Rheumnow Abst #0452 Raychaudhuri et al. TB-PET/CT indices ➡️ disease outcome measures in PsA Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS
swethaann23 swethaann23 ( View Tweet)
Can we predict who which PsA pts will be radiographic progressors? Abs#449 identified 103 candidate biomarker peptides corresponding to 69 proteins that could ID progressors More data needed #ACR21 @RheumNow https://t.co/OLfPRNjTKV https://t.co/6UTn1J7nJH

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PBO in active PsA at Week 16, with improvements in more refractory domains over 52 weeks. Safety consistent with other JAKi @RheumNow #ACR21 Abstr#0488 https://t.co/ugsV7uRwro

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

Interesting study on immune cell profiling in PsA pts ⭐️variability in T cell sub-populations in PsA pts ⭐️no difference in lymphocyte cell populations before/after therapy Abs#0056 https://t.co/16PYxaxT2S #ACR21 @RheumNow https://t.co/dWaJr7hJ1p

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. ▶️150 mg RZB vs Placebo ⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI ⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn ⭐️No safety signal https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd

Links:

Eric Dein ericdeinmd ( View Tweet)
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
TheDaoIndex KDAO2011 ( View Tweet)
Promising results of Risankizumab for #psoriaticarthritis 🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo 🔸Well tolerated and showed no safety signals @RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
sheila RHEUMarampa ( View Tweet)
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
Olga Petryna DrPetryna ( View Tweet)
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Abst 0452 #ACR21 #acrbest @RheumNow TB-PET/CT in PsA helps differentiate from RA/OA &measure inflammatory burden. Main findings asymmetric synovitis,systemic enthesitis, DIP& extensor tendons inflammation& adjacent nail matrix inflammation, Sacroiliitis& diffuse spine enthesitis https://t.co/7nTSIbmKfE
Olga Petryna DrPetryna ( View Tweet)
#Fatigue is common in pts w/ #PsA- what is the impact on short-term disability? Study of ~1200 pts finds greater annual short-term disability in pts with PsA & fatigue than w/o fatigue. Impact on QoL, work & socioeconomic costs. @RheumNow #ACR21 Abs#0239 https://t.co/9yNBOovm2L https://t.co/l4tn0TSld1

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Excited for the first full day of #ACR21, reporting for @RheumNow! Esp looking forward to: ⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes ⭐Plenary session ⭐Scientific sessions covering #axSpA, #PsA and more

Mrinalini Dey DrMiniDey ( View Tweet)

PsA bDMARD use in Australia🇦🇺 (where once you qualify for a bDMARD in general, it's the physician's free choice) 1. cool Sankey diagram showing switches 2. given the chance, people switch in all directions & switch hard (registry linked with insurance) #ACR21 ABST0201 @RheumNow https://t.co/jcVPa8jXsR
David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×